A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Clinical trial NCT05547061 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05547061
- Sponsor
- Cellbion Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-12
- Primary completion
- 2024-12-31
- Enrollment
- 91
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.